高收入与较低收入国家成人癌症患者的患者间期、诊断间期与治疗间期:系统综述与Meta分析
该系统综述与Meta分析纳入410篇文章、覆盖68个国家、5,537,594例患者,估计多种癌症的患者间期、诊断间期与治疗间期的中位时长,并比较高收入与较低收入国家。多数癌症患者间期在高收入国家一般不超过1个月,而较低收入国家几乎全部癌种的患者间期长1.5至4倍;诊断与治疗间期数据多来自高收入国家,诊断间期最长见于血液系统、泌尿生殖系统与消化系统癌症,治疗间期最长见于泌尿生殖系统与妇科癌症。
要点
- 较低收入国家几乎全部癌种的患者间期中位时长是高收入国家的1.5至4倍。
- 诊断间期最长见于血液系统癌症(71天)、泌尿生殖系统癌症(58天)与消化系统癌症(57天)。
- 治疗间期最长见于泌尿生殖系统癌症(57天)与妇科癌症(46天)。
核心结论
- 结果识别出诊断与治疗启动可能耗时最长的癌症,并揭示全球早期诊断与治疗方面的差异程度。
研究设计与样本
- 系统综述与Meta分析(前瞻性注册方案CRD42020200752),检索MEDLINE、Embase、Web of Science及灰色文献(Google Scholar、OpenGrey、EThOS、ProQuest Dissertations & Theses),纳入2009至2022年发表、报告成人原发性症状性癌症患者间期、诊断间期与治疗间期时长的文章。
- 共纳入410篇文章,覆盖68个国家,报告5,537,594例患者;其中294篇(72%)报告高收入国家数据,116篇(28%)报告较低收入国家数据。
- 采用Aarhus清单评估研究方法学质量,对38种癌症可进行汇总Meta分析估计。
主要发现
- 高收入国家研究中,多数癌症的患者间期汇总中位时长一般不超过1个月;较低收入国家研究中,几乎全部癌种的患者间期一致长1.5至4倍。
- 诊断间期最长见于血液系统癌症(71天,95%CI 52至85),如骨髓瘤(83天,95%CI 47至145);泌尿生殖系统癌症(58天,95%CI 50至77),如前列腺癌(85天,95%CI 57至112);消化系统癌症(57天,95%CI 45至67),如结直肠癌(63天,95%CI 48至78)。
- 治疗间期最长见于泌尿生殖系统癌症(57天,95%CI 45至66),如前列腺癌(75天,95%CI 61至87);妇科癌症(46天,95%CI 38至54),如宫颈癌(69天,95%CI 45至108)。
- 高收入国家研究中,实施癌症导向政策与多个癌种更短的患者间期和诊断间期相关。
关键数值与推荐
- 患者间期定义为从症状出现到首次就诊于医疗专业人员。
- 诊断间期定义为从首次就诊到确诊。
- 治疗间期定义为从确诊到治疗开始。
- 间期时长以天数记录,研究的中位数以95%CI汇总估计。
临床怎么用
- 作者认为,应努力减少较低收入国家癌症症状的求助时间。
局限性
- 本综述存在幸存者偏倚。
- 癌症治疗路径中时间点和间期的测量存在固有复杂性和许多可能的偏倚。
- 未考虑构成诊断间期的子间期(如初级保健间期、转诊至诊断间期)。
- 诊断与治疗间期的估计主要来自拥有强大卫生信息系统记录此类信息的高收入国家。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Longer time intervals to diagnosis and treatment are associated with worse survival for various types of cancer. The patient, diagnostic, and treatment intervals are considered core indicators for early diagnosis and treatment. This review estimated the median duration of these intervals for various types of cancer and compared it across high- and lower-income countries. METHODS AND FINDINGS: We conducted a systematic review with meta-analysis (prospectively registered protocol CRD42020200752). Three databases (MEDLINE, Embase, and Web of Science) and information sources including grey literature (Google Scholar, OpenGrey, EThOS, ProQuest Dissertations & Theses) were searched. Eligible articles were published during 2009 to 2022 and reported the duration of the following intervals in adult patients diagnosed with primary symptomatic cancer: patient interval (from the onset of symptoms to first presentation to a healthcare professional), diagnostic interval (from first presentation to diagnosis), and treatment interval (from diagnosis to treatment start). Interval duration was recorded in days and study medians were combined in a pooled estimate with 95% confidence intervals (CIs). The methodological quality of studies was assessed using the Aarhus checklist. A total of 410 articles representing 68 countries and reporting on 5,537,594 patients were included. The majority of articles reported data from high-income countries (n = 294, 72%), with 116 (28%) reporting data from lower-income countries. Pooled meta-analytic estimates were possible for 38 types of cancer. The majority of studies were conducted on patients with breast, lung, colorectal, and head and neck cancer. In studies from high-income countries, pooled median patient intervals generally did not exceed a month for most cancers. However, in studies from lower-income countries, patient intervals were consistently 1.5 to 4 times longer for almost all cancer sites. The majority of data on the diagnostic and treatment intervals came from high-income countries. Across both high- and lower-income countries, the longest diagnostic intervals were observed for hematological (71 days [95% CI 52 to 85], e.g., myelomas (83 days [47 to 145])), genitourinary (58 days [50 to 77], e.g., prostate (85 days [57 to 112])), and digestive/gastrointestinal (57 days [45 to 67], e.g., colorectal (63 days [48 to 78])) cancers. Similarly, the longest treatment intervals were observed for genitourinary (57 days [45 to 66], e.g., prostate (75 days [61 to 87])) and gynecological (46 days [38 to 54], e.g., cervical (69 days [45 to 108]) cancers. In studies from high-income countries, the implementation of cancer-directed policies was associated with shorter patient and diagnostic intervals for several cancers. This review included a large number of studies conducted worldwide but is limited by survivor bias and the inherent complexity and many possible biases in the measurement of time points and intervals in the cancer treatment pathway. In addition, the subintervals that compose the diagnostic interval (e.g., primary care interval, referral to diagnosis interval) were not considered. CONCLUSIONS: These results identify the cancers where diagnosis and treatment initiation may take the longest and reveal the extent of global disparities in early diagnosis and treatment. Efforts should be made to reduce help-seeking times for cancer symptoms in lower-income countries. Estimates for the diagnostic and treatment intervals came mostly from high-income countries that have powerful health information systems in place to record such information.
引用
- Petrova D, Špacírová Z, Fernández-Martínez NF, et al. The patient, diagnostic, and treatment intervals in adult patients with cancer from high- and lower-income countries: A systematic review and meta-analysis. PLoS Med. 2022. PMID: 36264841. doi:10.1371/journal.pmed.1004110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。